论文信息 - Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome. - 字舞流文

Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome.

M. Pfeffer | J. Tardif | M. Dubé

[1] M. Pfeffer,et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial , 2022, European heart journal.

[2] J. Tardif,et al. Adenylate cyclase type 9 antagonizes cAMP accumulation and regulates endothelial signaling involved in atheroprotection. , 2022, Cardiovascular research.

[3] S. Raychaudhuri,et al. A sex-specific evolutionary interaction between ADCY9 and CETP , 2021, bioRxiv.

[4] M. Pfeffer,et al. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib , 2021, Circulation. Genomic and precision medicine.

[5] S. Lévesque,et al. ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein) , 2018, Circulation.

[6] J. Tardif,et al. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib , 2015, Circulation. Cardiovascular genetics.